The FTC Second Request remains the key gating item for the Sanara acquisition; watch for any FTC action or deal termination risk. The Wound segment's 71% revenue decline and lowered full-year guidance suggest continued headwinds from Medicare reimbursement changes, making Q4 2026 results critical to assess whether stabilization is occurring.
Price Chart
Executive Summary
MiMedx Group reported Q3 2026 net sales of $62 million, down 45% YoY from $114 million, driven by a 71% decline in Wound sales due to Medicare reimbursement changes, partially offset by 9% Surgical sales growth. The company returned to positive Adjusted EBITDA of $2 million, announced a $25 million patent license agreement, and reiterated commitment to its pending acquisition of Sanara MedTech despite an ongoing FTC Second Request review.
Key Financial Metrics
Key Facts
- Q3 2026 net sales of $62 million, down 45% YoY from $114 million
- Surgical sales grew 9% YoY to $40 million; Wound sales fell 71% YoY to $22 million
- GAAP net loss of $9 million vs net income of $17 million in Q3 2025
- Adjusted EBITDA of $2 million, returning to positive vs negative $8 million in Q2 2026
- 2026 net sales guidance lowered to $250-$260 million
- Announced $25 million patent license agreement with a wound care competitor, paid in five annual $5 million installments
- Favorable federal court ruling on AXIOFILL regulatory classification, remanded to FDA
- FTC Second Request process ongoing for Sanara MedTech acquisition; deal not yet cleared
- Cash and cash equivalents of $121 million; no debt outstanding after repaying $17 million term loan
- Sanara acquisition consideration: $35 per share ($33 cash + 0.4735 MiMedx shares), total enterprise value approximately $350 million
Financial Impact
Net sales declined 45% YoY ($62M vs $114M), GAAP net loss of $9M vs net income of $17M, Adjusted EBITDA of $2M vs $35M. Full-year 2026 guidance reduced to $250-$260M.
Risk Factors
- FTC may block or impose conditions on the Sanara acquisition, or the deal may be delayed or terminated
- Wound Care revenue continues to be severely impacted by Medicare reimbursement changes with no clear recovery timeline
- Lowered 2026 net sales guidance to $250-$260 million implies ongoing top-line pressure
- Patent license agreement payments are spread over five years, limiting near-term cash benefit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001376339-26-000096 |
| Document: 0001376339-26-000096-index-headers.html | 0001376339-26-000096 |
| Document: 0001376339-26-000096-index.html | 0001376339-26-000096 |
| Document: 0001376339-26-000096.txt | 0001376339-26-000096 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 today | 8-K | $33.10 | awaiting T+5 | awaiting T+5 | $32.92 (−0.56%) |
Oct 28, 2026 1d ago | 425 | $32.92 | awaiting T+5 | awaiting T+5 | $32.92 (+0.02%) |
Oct 16, 2026 13d ago | 425 | $33.16 $32.80 | ▲ +1.09% | ▲ +1.18% | $32.92 (+0.74%) |
Oct 16, 2026 13d ago | 8-K | $33.16 $32.80 | ▼ −1.09% | ▼ −1.18% | $32.92 (−0.74%) |
Jul 30, 2026 13w ago | 425 | $34.06 $34.09 | ▲ +0.09% | ▼ −3.53% | $32.92 (−3.36%) |
Jul 30, 2026 13w ago | 425 | $34.06 $34.09 | ▲ +0.09% | ▼ −3.53% | $32.92 (−3.36%) |
Jul 30, 2026 13w ago | 425 | $34.06 $34.09 | ▲ +0.09% | ▼ −3.53% | $32.92 (−3.36%) |
Jul 30, 2026 13w ago | 425 | $34.06 $34.09 | ▲ +0.09% | ▼ −3.53% | $32.92 (−3.36%) |
Jun 4, 2026 21w ago | 8-K | $22.44 $20.81 | ▼ −7.26% | ▼ −7.83% | $32.92 (+46.68%) |
May 11, 2026 24w ago | 8-K | $20.44 $21.89 | ▲ +7.09% | ▲ +7.02% | $32.92 (+61.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers